Horizon Pharma (HZNP) Tops Q2 EPS by 31c, Raises Guidance

August 7, 2017 7:06 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Horizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.41, $0.31 better than the analyst estimate of $0.10. Revenue for the quarter came in at $289.5 million versus the consensus estimate of $237.1 million.


Horizon Pharma sees FY2017 revenue of $1.01-1.05 million, versus the consensus of $991.3 million.

  • increased its full-year 2017 adjusted EBITDA guidance to $340 million to $375 million from $315 million to $350 mill

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities